

# Huojun Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6053780/publications.pdf>

Version: 2024-02-01

31  
papers

460  
citations

687363

13  
h-index

752698

20  
g-index

35  
all docs

35  
docs citations

35  
times ranked

680  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 101-110.	0.8	52
2	Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 82, 545-551.	5.5	33
3	Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, e105-e115.	10.7	29
4	Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. <i>Cancer Medicine</i> , 2017, 6, 2263-2270.	2.8	28
5	Discovery of benzothiazole derivatives as novel non-sulfamide NEDD8 activating enzyme inhibitors by target-based virtual screening. <i>European Journal of Medicinal Chemistry</i> , 2017, 133, 174-183.	5.5	26
6	Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. <i>Journal of Controlled Release</i> , 2020, 324, 545-559.	9.9	19
7	Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer. <i>Radiation Oncology</i> , 2018, 13, 205.	2.7	18
8	Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. <i>Cancer Medicine</i> , 2018, 7, 2913-2924.	2.8	16
9	Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score). <i>Radiotherapy and Oncology</i> , 2018, 129, 313-318.	0.6	15
10	Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1). <i>Radiation Oncology</i> , 2019, 14, 52.	2.7	15
11	Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matched analysis of a prospectively collected database. <i>Cancer Management and Research</i> , 2018, Volume 10, 1295-1304.	1.9	14
12	Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China. <i>Scientific Reports</i> , 2020, 10, 7836.	3.3	14
13	Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097715.	3.2	14
14	Discovery of 7- <i>N</i> -Methyl-1,4-dihydroxyhomocamptothecins with 1,2,3,4-tetrazole Moiety as Potent Topoisomerase I Inhibitors. <i>Chemical Biology and Drug Design</i> , 2016, 88, 398-403.	3.2	12
15	Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial. <i>BMJ Open</i> , 2016, 6, e013220.	1.9	11
16	Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. <i>Cancer Science</i> , 2021, 112, 287-295.	3.9	11
17	Diagnostic value of [18F] FDG-PET and PET/CT in urinary bladder cancer: a meta-analysis. <i>Tumor Biology</i> , 2015, 36, 3209-3214.	1.8	9
18	Phosphorothioate-modified antisense oligonucleotides against human telomerase reverse transcriptase sensitize cancer cells to radiotherapy. <i>Molecular Medicine Reports</i> , 2017, 16, 2089-2094.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting auto-shells. <i>Radiation Oncology</i> , 2018, 13, 11.	2.7	9
20	The clinical efficacy and safety of neoadjuvant chemoradiation therapy with immunotherapy for the organ preservation of ultra low rectal cancer: A single arm and open label exploratory study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e15603-e15603.	1.6	9
21	Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 59, 116672.	3.0	8
22	Analysis of the factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular carcinoma patients. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5289-5295.	2.0	6
23	Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pancreatic cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 4805-4815.	1.9	6
24	Promoting Inter-/Intra- Cellular Process of Nanomedicine through its Physicochemical Properties Optimization. <i>Current Drug Metabolism</i> , 2018, 19, 75-82.	1.2	5
25	Combination of Pre-Treatment DWI-Signal Intensity and S-1 Treatment: A Predictor of Survival in Patients with Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy and Sequential S-1. <i>Translational Oncology</i> , 2018, 11, 399-405.	3.7	4
26	Proteomic Analysis of Radiation-Induced Acute Liver Damage in a Rabbit Model. <i>Dose-Response</i> , 2019, 17, 155932581988950.	1.6	4
27	Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single-arm, phase 2 trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 178-184.	0.6	4
28	Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 688576.	2.8	3
29	Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Consecutive Cases. <i>Frontiers in Oncology</i> , 2021, 11, 729490.	2.8	2
30	Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e424.	10.7	1
31	Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of modifications. <i>Cancer Biology and Medicine</i> , 2020, 17, 492-500.	3.0	1